Assessments
dementia
ADVERSE EVENT
During the 24-week assessment period, clinical efficacy was measured at week-0, week-8, week-12, and week-24 according to the following instruments: 11-item ADAS-cog (scores range from 0 to 70, with higher scores indicating worse dementia) [Patients were monitored for safety from the date of informed consent until 28 days after discontinuing the study drug. Safety for each masitinib dose level was compared against a pooled placebo population and expressed in terms of incidence rate ratio (IRR) (i.e., the incidence rate of masitinib divided by that of pooled placebo). Adverse events were coded according to the MedDRA dictionary version 20.0.